Product focus
Recovery, body-composition, sleep, and growth-hormone-axis support.
THECARE / PRODUCT PROTOCOL
Combination formulaCJC-1295 w/ DAC / Ipamorelin(10 mg + 10 mg)
Your guide to preparation, dosing & use.
Vial strength10 mg/10 mg per vial
After preparation20 mg / 2 ml
AdministrationSubcutaneous (SQ)
01
PRODUCT INFORMATION
Benefits
Formulation
2X Blend CJC-1295 w/DAC / Ipamorelin
Who it is intended for
Clients who match the protocol goal for this product and have no safety exclusions.
02
WHAT TO WATCH FOR
Side Effects
Mild edema, joint pain, and injection redness.
When to pause and get help
Pause use and get help for red flag symptoms, unexpected side effects, dose errors, missed doses with symptoms, pregnancy, new diagnosis, new medication, or uncertainty about storage/reconstitution.
03
WHEN TO GET HELP
Adverse Effects
URGENT SYMPTOMS
Get urgent medical help.
Severe allergic reaction, trouble breathing, chest pain, fainting, severe abdominal pain, persistent vomiting, severe swelling, infection signs, or rapidly worsening symptoms require urgent medical help.
Who needs a safety review?
Before using this product
Pregnant/breastfeeding clients, minors, clients with active infection, uncontrolled medical conditions, severe allergies, or complex medication histories should complete safety review before use. Cancer history, endocrine disorders, uncontrolled diabetes, edema, or growth-hormone-axis concerns should complete safety review before use.
Conditions and medicines to review
Pregnant/breastfeeding clients, minors, clients with active infection, uncontrolled medical conditions, severe allergies, or complex medication histories should complete safety review before use. Cancer history, endocrine disorders, uncontrolled diabetes, edema, or growth-hormone-axis concerns should complete safety review before use. Disclose all prescriptions, OTC medications, supplements, allergies, and prior reactions.
04
MEASURE CORRECTLY
Dosing Guide
YOUR DOSE · FOLLOW YOUR PRESCRIPTION
10 units SQ, 5 days on and 2 days off.
Units refer to U-100 syringe markings.
Doses per vial
20 × 10-U; 4 weeks at 5 injections per week.
Dose changes
Change your dose only when your care team gives you the new amount and start date.
U-100 syringe conversion
For CJC-1295 w/ DAC 10 mg, Ipamorelin 10 mg in 2 mL after preparation.
Swipe sideways to see each ingredient →
| Syringe mark U-100 | Volume mL | CJC-1295 w/ DAC mg | Ipamorelin mg |
|---|---|---|---|
| 1 | 0.01 | 0.05 | 0.05 |
| 5 | 0.05 | 0.25 | 0.25 |
| 10 | 0.10 | 0.5 | 0.5 |
| 20 | 0.20 | 1 | 1 |
| 25 | 0.25 | 1.25 | 1.25 |
| 50 | 0.50 | 2.5 | 2.5 |
1 U-100 marking = 0.01 mL. Multiply the amount per vial by the mL drawn, then divide by the final mL in the vial. Amounts are rounded for display; match the vial label and written order.
Preparation & storage
Mixing instructions
Add 2 ml BAC water to the vial. Inject it slowly down the inside wall of the vial, then gently swirl until dissolved; do not shake. Use sterile technique.
Package contents
Product vial.
Supplies
Confirm syringes, needles, alcohol pads, BAC water, and disposal supplies are included or available before starting.
Before mixing / opening
Store at the temperature on your product label. Protect from light and follow the expiry date.
After mixing
Write the mixing date on your vial. Follow its storage temperature and discard date. Discard any remaining solution on that date.
If the package arrives warm
Do not use if package integrity is questionable. Contact support for review and keep product per storage instructions while awaiting guidance.
05
USE & FOLLOW-UP
Protocol
Route
Self-injection: SQ (subcutaneous)
Injection site
Abdomen ≥2 inches (5 cm) from navel, side of abdomen, outer middle thigh, or back of upper arm with a trained helper. Rotate and avoid damaged skin.
Subcutaneous injection: choose a site
Abdomen
Choose fatty tissue at least 2 inches (5 cm) from the navel.
Side of abdomen
Choose healthy fatty tissue below the ribs and above the hip bone.
Back of upper arm
A trained helper can use the fatty tissue on the back of the upper arm.
Outer thigh
Choose fatty tissue on the outer middle thigh, away from the knee and hip.
45° and 90° examples
These illustrations identify tissue layers and example angles; they are not to scale. Needle length, angle and whether to lift a fold depend on the prescribed device and your training; stop and ask the clinic if either is unspecified.
Check the order and equipment
Match name, vial strength, final concentration, SQ route, expiration and discard date to your prescription. Use the prescribed U-100 syringe only if the order specifies it; its marks measure volume.
Prepare and measure
Wash and dry hands. Use a clean surface, a new sterile needle and syringe, and an alcohol pad. Check solution appearance, clean the stopper and let it dry. Draw only the prescribed volume and recheck the mark and bubbles.
Choose and clean a site
Choose one healthy site shown above and rotate each time. Avoid red, hard, bruised, scarred or tender skin. Clean the spot and let it dry. Do not touch it again.
Inject into fatty tissue
Gently lift a skin-and-fat fold if your training calls for it. Use the 45° or 90° angle specified for your needle and body habitus. Insert into fat, press the plunger steadily, then withdraw at the same angle.
Finish and dispose
Press clean gauze if needed; do not rub. Do not recap or reuse the needle. Put needle and syringe immediately in a sharps container; close it at about three-quarters full and use local disposal rules.
Missed dose or error
Do not double, repeat, or titrate without the written order. Contact the clinic for a discrepancy, uncertain storage, or unexpected reaction; urgent symptoms need emergency care.
Refills and switching
When to reorder
Reorder before the earlier of measured supply and the dispensing label's discard date; confirm the active course and dose.
Before a refill
Current dose, frequency, response, side effects, weight/goal changes if relevant, missed doses, remaining supply, and any new medications or medical changes.
Before switching
Previous product name, dose, last injection date, side effects, response, reason for switching, current medications, and confirmation that switching is appropriate.